0,1,2,3,4,5,6
"Table 6.1.10: Selected studies of ADT in combination with, or without, RT for PCa",,,,,,
"PCSIII
2020 [683]","Intermediate 
risk",600,"76 Gy alone 
vs. 
76 Gy + ADT 
vs. 
70 Gy + ADT","LHRH + 
bicalutamide
6 mo.
4 mo. prior to 
RT",70 vs. 76 Gy,"Significantly improved 
biochemical failure-
free and PCa-specific 
survival for ADT arms, 
with no difference in 
OS."
Study,TNM stage,n,Trial design,ADT,RT,Effect on OS
"SPCG-7/ 
SFUO-3 
2016 [684]","T1b–2 WHO 
Grade 1–3,  
T3 N0 M0",875,ADT ± EBRT,"LHRH agonist 
for 3 mo. plus 
continuous 
flutamide","70 Gy 
3D-CRT 
vs. no RT","34% (95% CI: 29–39%) 
vs. 17% (95% CI: 13–22% 
CSM at 12 (15) yr. favouring 
combined treatment 
(p < 0.0001 for 15-yr. results)  
NCIC CTG PR.3/MRC"
"PRO7/NCIC 
2015 [685]","T3–4 (88%),  
PSA > 20 ng/mL  
(64%), ISUP 
grade 4–5 (36%) 
N0 M0","1,205",ADT ± EBRT Continuous,LHRH agonist,"65–70 Gy 
3D-CRT 
vs. no RT","10-yr. OS = 49% vs. 55%  
favouring combined 
treatment HR: 0.7, 
p < 0.001)"
"Sargos, et al. 
2020 [686]",T3–4 N0 M0,273,ADT ± EBRT,"LHRH agonist 
for 3 yr.","70 Gy 
3D-CRT 
vs. no RT","Significant reduction of 
clinical progression; 5-yr. 
OS 71.4% vs. 71.5%"
